UNITED LAB's Insulin Degludec Injection Receives Market Approval

Stock News03-09

UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Insulin Degludec Injection. The approved specifications are 3ml:300 units (cartridge) and 3ml:300 units (pre-filled pen), with drug approval numbers S20260015 and S20260016, respectively. Insulin Degludec is a new-generation ultra-long-acting basal insulin analog indicated for the treatment of adult diabetes. It can be used alone or in combination with oral hypoglycemic agents or mealtime insulin to comprehensively meet long-term clinical blood glucose management needs. Administered via once-daily subcutaneous injection, it offers ultra-long and stable glucose control, high safety, and flexible dosing timing. The product has been included in the National Reimbursement Drug List (2025 edition) as a Category B drug, providing significant advantages in accessibility and cost-effectiveness. This approval marks another key technological breakthrough for the company in the field of diabetes. Moving forward, UNITED LAB will continue to focus on the research and development of new products, with an emphasis on enhancing its competitiveness and innovation capabilities in the biopharmaceutical industry. The company aims to deepen its presence in the chronic disease treatment sector, delivering higher-quality products and a more comprehensive pipeline to better serve clinical needs and benefit patients, which is expected to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153681835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153681835","market":"fut","top_or_hot":-1,"title":"UNITED LAB's Insulin Degludec Injection Receives Market Approval","media":"Stock News","content":"<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Insulin Degludec Injection. The approved specifications are 3ml:300 units (cartridge) and 3ml:300 units (pre-filled pen), with drug approval numbers S20260015 and S20260016, respectively. Insulin Degludec is a new-generation ultra-long-acting basal insulin analog indicated for the treatment of adult diabetes. It can be used alone or in combination with oral hypoglycemic agents or mealtime insulin to comprehensively meet long-term clinical blood glucose management needs. Administered via once-daily subcutaneous injection, it offers ultra-long and stable glucose control, high safety, and flexible dosing timing. The product has been included in the National Reimbursement Drug List (2025 edition) as a Category B drug, providing significant advantages in accessibility and cost-effectiveness. This approval marks another key technological breakthrough for the company in the field of diabetes. Moving forward, UNITED LAB will continue to focus on the research and development of new products, with an emphasis on enhancing its competitiveness and innovation capabilities in the biopharmaceutical industry. The company aims to deepen its presence in the chronic disease treatment sector, delivering higher-quality products and a more comprehensive pipeline to better serve clinical needs and benefit patients, which is expected to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB's Insulin Degludec Injection Receives Market Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB's Insulin Degludec Injection Receives Market Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-09 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Insulin Degludec Injection. The approved specifications are 3ml:300 units (cartridge) and 3ml:300 units (pre-filled pen), with drug approval numbers S20260015 and S20260016, respectively. Insulin Degludec is a new-generation ultra-long-acting basal insulin analog indicated for the treatment of adult diabetes. It can be used alone or in combination with oral hypoglycemic agents or mealtime insulin to comprehensively meet long-term clinical blood glucose management needs. Administered via once-daily subcutaneous injection, it offers ultra-long and stable glucose control, high safety, and flexible dosing timing. The product has been included in the National Reimbursement Drug List (2025 edition) as a Category B drug, providing significant advantages in accessibility and cost-effectiveness. This approval marks another key technological breakthrough for the company in the field of diabetes. Moving forward, UNITED LAB will continue to focus on the research and development of new products, with an emphasis on enhancing its competitiveness and innovation capabilities in the biopharmaceutical industry. The company aims to deepen its presence in the chronic disease treatment sector, delivering higher-quality products and a more comprehensive pipeline to better serve clinical needs and benefit patients, which is expected to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1153681835","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153681835","pubTimestamp":1773045600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained marketing approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03933":"联邦制药"},"translate_title":"联邦制药德谷胰岛素注射液获上市批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Insulin Degludec Injection. The approved specifications are 3ml:300 units (cartridge) and 3ml:300 units (pre-filled pen), with drug approval numbers S20260015 and S20260016, respectively. Insulin Degludec is a new-generation ultra-long-acting basal insulin analog indicated for the treatment of adult diabetes. It can be used alone or in combination with oral hypoglycemic agents or mealtime insulin to comprehensively meet long-term clinical blood glucose management needs. Administered via once-daily subcutaneous injection, it offers ultra-long and stable glucose control, high safety, and flexible dosing timing. The product has been included in the National Reimbursement Drug List (2025 edition) as a Category B drug, providing significant advantages in accessibility and cost-effectiveness. This approval marks another key technological breakthrough for the company in the field of diabetes. Moving forward, UNITED LAB will continue to focus on the research and development of new products, with an emphasis on enhancing its competitiveness and innovation capabilities in the biopharmaceutical industry. The company aims to deepen its presence in the chronic disease treatment sector, delivering higher-quality products and a more comprehensive pipeline to better serve clinical needs and benefit patients, which is expected to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153681835","isCrawlerRequest":true}